Berenberg Bank Remains a Buy on AbCellera Biologics (ABCL)

In a report released today, Gaurav Goparaju from Berenberg Bank maintained a Buy rating on AbCellera Biologics (ABCLResearch Report), with a price target of $43.00. The company’s shares closed yesterday at $12.24.

According to TipRanks, Goparaju is an analyst with an average return of -25.4% and a 24.39% success rate. Goparaju covers the Technology sector, focusing on stocks such as Schrodinger, Berkeley Lights, and Certara.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for AbCellera Biologics with a $37.75 average price target.

See today’s best-performing stocks on TipRanks >>

ABCL market cap is currently $3.49B and has a P/E ratio of 17.36.

Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ABCL in relation to earlier this year. Most recently, in August 2022, Hansen Carl L. G., the CEO of ABCL bought 56,125.00 shares for a total of $151,537.50.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

AbCellera Biologics Inc is a biotechnology company. The company develops antibodies to treat highly infectious diseases and various other types of diseases.

Read More on ABCL:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More